Last updated on December 2018

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)


Brief description of study

The OMS/DES study is a multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome.

This trial brought on the way by specialists of the EPNS (European Paediatric Neurology Society), the GPOH (Gesellschaft fr Pdiatrische Hematologic und Oncologie) and the SIOPEN (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).

This protocol will investigate an escalating treatment schedule starting with a corticosteroid standard treatment with dexamethasone pulses (first step), which is followed, if response has been inadequate after 3 months of treatment, by the addition of CP (second step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES severity.

Clinical Study Identifier: NCT01868269

Find a site near you

Start Over

Chu de Bicetre

Le Kremlin-Bicêtre, France
  Connect »

Chu Amiens

Amiens, France
  Connect »

Chu Angers

Angers, France
  Connect »

Chr Pellegrin

Bordeaux, France
  Connect »

Chu D'Estaing

Clermont Ferrand, France
  Connect »

Chu Dijon

Dijon, France
  Connect »

Chu Saint Etienne

Saint-Étienne, France
  Connect »

Hopital Nancy Brabois

Vandoeuvre Les Nancy, France
  Connect »